|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.32 USD | -1.71% |
|
-2.64% | -30.03% |
| 06-02 | Daxor Says Received US Patent for Remote Blood Volume Monitor Technology | MT |
| 04-27 | 5,061,267 Common Stock of Daxor Corporation are subject to a Lock-Up Agreement Ending on 27-APR-2026. | CI |
Company Valuation: Daxor Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| Market Cap 1 | 45.52 | 37.22 | 73.52 | 60.14 | - |
| Change | - | - | 97.53% | -18.2% | - |
| Enterprise Value (EV) | 45.52 | 37.22 | 73.52 | 60.14 | 60.14 |
| Change | - | - | 97.53% | -18.2% | 0% |
| P/E | - | - | 8.02x | -49.1x | -344x |
| PBR | - | - | - | - | - |
| PEG | - | - | - | 0x | 4x |
| Capitalization / Revenue | 164x | 311x | 2,755x | 5.05x | 2.89x |
| EV / Revenue | 0x | 0x | 0x | 5.05x | 2.89x |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | - | - | -0x | -50.1x | -301x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | - | - | 1.839 | -0.21 | -0.03 |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | 0.2781 | 0.1197 | 0.0267 | 11.9 | 20.8 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | - | -1.107 | -1.2 | -0.2 |
| Net income 1 | 4.748 | 0.5363 | 9.17 | -1.2 | -0.2 |
| Net Debt | - | - | - | - | - |
| Reference price 2 | 11.28 | 7.69 | 14.75 | 10.32 | 10.32 |
| Nbr of stocks (in thousands) | 4,034 | 4,840 | 4,984 | 5,827 | - |
| Announcement Date | 28/02/22 | 03/03/25 | 02/03/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- DXR Stock
- DXR Stock
- Valuation Daxor Corporation
Select your edition
All financial news and data tailored to specific country editions
